Cognitive
DSIP
Delta Sleep-Inducing Peptide — a nonapeptide studied for sleep onset and delta-wave enhancement.
- Half-life
- Short (minutes); effects attributed to CNS modulation rather than plasma persistence.
- Route
- Subcutaneous
Overview
DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid peptide originally isolated from the cerebral venous blood of sleeping rabbits. It has been investigated for its ability to promote sleep and modulate circadian rhythms.
Mechanism of action
Modulates monoaminergic and GABAergic systems, influences delta-wave sleep architecture, and may interact with endocrine pathways including cortisol and GH secretion timing.
Evidence base
Preclinical studies show increased slow-wave sleep and reduced sleep latency. Human trials are limited and heterogeneous; some report improved sleep quality and reduced chronic pain in insomnia patients.
Typical dosing
Research protocols commonly cite 100–300 mcg subcutaneously, 30–60 minutes before bedtime, for 10–20 day cycles. Open the dose calculator →
Safety & contraindications
Generally reported as well tolerated with no sedation or hangover. Human safety data remain limited; not approved by any major regulator.
Featured in protocols
Related peptides
Educational reference only. Nothing on this page is medical advice, a prescription, or an offer to sell. Discuss any peptide therapy with a qualified clinician who can evaluate your history and monitoring needs.